The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

Phenylbutyl isoselenocyanate (ISC-4) is an Akt inhibitor with demonstrated preclinical efficacy against melanoma and colon cancer. In this study, we sought to improve the clinical utility of ISC-4 by identifying a synergistic combination with FDA-approved anti-cancer therapies, a relevant and approp...

Full description

Bibliographic Details
Main Authors: Joshua E Allen, Jean-Nicolas Gallant, David T Dicker, Shantu Amin, Rosalyn B Irby, Arun K Sharma, Wafik S El-Deiry
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3595267?pdf=render

Internet

http://europepmc.org/articles/PMC3595267?pdf=render

Similar Items